news

May 27, 2021

Pieris Pharmaceuticals declares Respiratory and Ophthalmology deal with Genentech Pieris, a clinical-stage biotechnology company, declared that it has entered into a multi-program research collaboration and license collaboration with Genentech, a member of the Roche Group, to discover, develop and commercialise ...

May 13, 2021

Lilly, MiNA ink agreement to upregulate proteins using RNA Eli Lilly will utilise the power of MiNA Therapeutics’ proprietary small activating RNA (saRNA) technology platform to develop five novel drug candidates against diseases across the company’s core areas of focus. Eli Lilly declared a drug development ...

May 06, 2021

Pfizer suffers a DMD delay and halts BCMA trials amid safety woes  Pfizer has paused after seeing three cases of peripheral neuropathy in an early-stage study, enrollment in a critical analysis of its anti-BCMA bispecific antibody. Big Pharma shares news with details of delays to the start of the US part of...

Apr 29, 2021

Arch Oncology scores USD 105 Million for anti-CD47 med in solid tumors, multiple myeloma Arch Oncology scored USD 105 million from new and old backers to expand the drug’s journey through the clinic and into new trials, having moved its anti-CD47 antibody into a phase 1/2 study.  Arch tests the drug alon...

Apr 22, 2021

Vertex leads in CRISPR Therapeutics partnership with USD 900 Million upfront Vertex has boosted a deal with CRISPR Therapeutics to USD 900 million upfront as the companies compete against bluebird bio to the market with a novel gene-editing therapy for sickle cell disease and beta-thalassemia called CTX001. B...

Apr 15, 2021

Lilly’s RET inhibitor Retevmo exhibits early promise in new cancer types The phase 1/2 LIBRETTO-001 trial enrolled 32 patients with 12 unique RET fusion-positive advanced cancer types, comprising pancreatic, colon, breast and salivary cancer, with 62.5% affected by gastrointestinal tumours. Across all 32 pati...

Apr 13, 2021

Taysha takes charge of a Rare Disease Gene Therapy for $5.5 M  Taysha Gene Therapies announced the acquisition of exclusive global rights to TSHA-120 from a leading patient advocacy group for an upfront payment of USD 5.5 million.  TSHA-120 is an intrathecally dosed AAV9 gene therapy designed to tre...

Apr 08, 2021

Artios Pharma announces collaboration with Novartis to tap next-generation DDR cancer therapies Artios Pharma Limited, a leading DNA Damage Response (DDR) company exploiting synthetic lethality to create a broad pipeline of precision medicines for cancer treatment, announced a global research collaboration with ...

Apr 01, 2021

Amgen to acquire Rodeo Therapeutics for USD 55 Million Upfront  Amgen Inc. and Rodeo Therapeutics Corporation announced a deal under which Amgen will take over Rodeo, a privately-held biopharmaceutical company based in Seattle, which develops small-molecule therapies to enhance regeneration and repair of se...

Mar 25, 2021

Asher Bio raises USD 55 Million in Series A financing Asher Biotherapeutics, a biotechnology company developing exactly targeted immunotherapies for cancer and other diseases, raised USD 55 Million in Series A financing. Third Rock Ventures led the round with participation from Boxer Capital of Tavistock Grou...